Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2023 | Post-hoc analysis of OPTIC: patient responses to ponatinib by T315I mutational status

Jorge Cortes • 7 Sep 2023

SOHO 2023

Chronic Myeloid Leukemia Leukemia Ponatinib

OPTIC

Jorge Cortes, MD, Augusta University, Augusta, GA, briefly discusses the results of a post-hoc analysis of the OPTIC trial (NCT02467270) evaluating patient responses to ponatinib based on T315I mutational status. In this trial, ponatinib was administered at doses of 45 mg, 30 mg, and 15 mg, and outcomes were determined in three patient groups according to the presence of T315I mutation, other mutations, or no mutations. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Key emerging trials in CML and the importance of improving treatment-free remission rates

Jorge Cortes • 7 Sep 2023

Social determinants of health & their impact on patients with hematological malignancies

Jorge Cortes • 7 Sep 2023

Exciting updates in the field of CML: disease pathophysiology & novel agents

Jorge Cortes • 7 Sep 2023

Cardiotoxicity of CPX-351 vs 7+3 chemotherapy in patients with untreated high-risk AML

Jorge Cortes • 9 Jun 2023

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024